Virtu Financial LLC bought a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 98,869 shares of the biotechnology company’s stock, valued at approximately $198,000. Virtu Financial LLC owned 0.25% of Aptose Biosciences as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds have also recently bought and sold shares of the business. Noven Financial Group Inc. purchased a new stake in shares of Aptose Biosciences in the 4th quarter worth $27,000. Geode Capital Management LLC purchased a new stake in shares of Aptose Biosciences in the 4th quarter worth $33,000. Citadel Advisors LLC purchased a new stake in shares of Aptose Biosciences in the 3rd quarter worth $125,000. Patriot Financial Group Insurance Agency LLC increased its stake in shares of Aptose Biosciences by 11.4% in the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 57,429 shares of the biotechnology company’s stock worth $110,000 after purchasing an additional 5,890 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Aptose Biosciences by 1,130.9% in the 3rd quarter. Renaissance Technologies LLC now owns 183,401 shares of the biotechnology company’s stock worth $477,000 after purchasing an additional 168,501 shares in the last quarter. Hedge funds and other institutional investors own 7.78% of the company’s stock.
Several equities research analysts have recently commented on APTO shares. Zacks Investment Research upgraded Aptose Biosciences from a “hold” rating to a “buy” rating and set a $2.50 price objective for the company in a research note on Monday, May 13th. Royal Bank of Canada assumed coverage on Aptose Biosciences in a research note on Friday, March 1st. They issued an “outperform” rating and a $6.00 price target for the company. Citigroup assumed coverage on Aptose Biosciences in a research note on Friday, January 25th. They issued an “outperform” rating and a $6.00 price target for the company. HC Wainwright set a $9.00 price target on Aptose Biosciences and gave the stock a “buy” rating in a research note on Friday, March 22nd. Finally, Oppenheimer assumed coverage on Aptose Biosciences in a research note on Thursday, January 24th. They issued an “outperform” rating and a $6.00 price target for the company. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $5.75.
In other news, CFO Gregory K. Chow acquired 15,000 shares of the firm’s stock in a transaction on Wednesday, March 13th. The stock was acquired at an average price of $1.75 per share, with a total value of $26,250.00. Following the completion of the purchase, the chief financial officer now directly owns 122,014 shares in the company, valued at $213,524.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Erich Platzer sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $2.19, for a total transaction of $43,800.00. The disclosure for this sale can be found here. In the last ninety days, insiders purchased 35,000 shares of company stock valued at $63,750. 7.34% of the stock is owned by insiders.
Shares of Aptose Biosciences stock traded down $0.02 during trading on Wednesday, reaching $1.98. 157,765 shares of the stock traded hands, compared to its average volume of 252,390. The firm has a market cap of $82.21 million, a price-to-earnings ratio of -2.30 and a beta of 1.57. The company has a quick ratio of 5.93, a current ratio of 5.93 and a debt-to-equity ratio of 0.09. Aptose Biosciences Inc. has a 52-week low of $1.57 and a 52-week high of $4.55.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.14) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.03. On average, equities analysts expect that Aptose Biosciences Inc. will post -0.66 EPS for the current fiscal year.
Aptose Biosciences Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Featured Article: What is insider trading?
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.